Complete Story
02/01/2019
WPS Oncology Related LCD Updates
February 2019
Febuary 2019 Local Coverage Determination (LCD)/Coverage Article Updates
The following is a summary of the Local Coverage Determination (LCD) and Coverage Article updates made by WPS GHA for February 2019. Additional details about these updates are available in the full article on our website.
New Policies/Articles - Effective March 19, 2019
- Human Granulocyte/Macrophage Colony Stimulating Factors Billing and Coding Guidelines
- MolDX: clonoSEQ® Assay for Assessment of Minimal Residual Disease (MRD) in Patients with Specific Lymphoid Malignancies
Retired Policies/Articles - Effective as Indicated
- Human Granulocyte/Macrophage Colony Stimulating Factor - Effective March 18, 2019
- MolDX: Pigmented Lesion Assay (PLA) and PLA Score - Effective February 1, 2019
Revised Policies/Articles - Effective as Indicated
- 2019 MolDX CPT/HCPCS Code Updates - Effective January 1, 2019
- Drug Administration Coding - Effective February 1, 2019
- Human Granulocyte/Macrophage Colony Stimulating Factor - Effective February 1, 2019
- MolDX: Coding and Billing for Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia - Effective July 20, 2018
- MolDX: CYP2C19, CYP2D6, CYP2C9, and VKORC1 Genetic Testing - Effective February 1, 2019
To access Local Coverage Determinations (LCDs) and Coverage Articles from the WPS GHA website, please visit our Local Coverage Determinations (LCDs) and Coverage Articles web page.
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
